Reduce Time, Effort and Cost in Bioprocessing for Cell and Gene Therapy

To meet increased throughput and safety demands, scientists at BridgeBio Pharma, Inc. and REGENXBIO Inc. are making use of the novel approach of AAV capsid titer quantification with label-free biosensor assays, which offers a robust alternative to conventional ELISA approaches.

Octet^® BLI instruments are eliminating hands-on steps that come with running a traditional immunoassay. Time and human error are significantly decreased, both factors that adversely impact assay reproducibility and team productivity.

Read Application Note

A rapid and robust method for AAV capsid quantitation is essential for AAV bioprocess development and manufacturing. Conventional ELISA, HPLC and ddPCR methods for AAV titer measurement are time-consuming and labor intensive.

The Octet^® Bio-Layer Interferometry (BLI) Platform - using the Octet^® AAVX Biosensors - provides a label-free approach with a broad dynamic range from 8.5 x 108 to 1.0 x 1013 vp/mL for all serotypes tested. It also shows high precision and accuracy for capsid quantitation of both purified and crude AAV samples and can be regenerated and re-used up to 20 times providing an efficient and cost-effective solution for high-throughput AAV quantitation applications. 

Read Technical Note